S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
The Largest Ever Technology Wave Is Coming! (Ad)
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:VERU

Veru (VERU) Stock Forecast, Price & News

$1.04
+0.01 (+0.97%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$1.02
$1.10
50-Day Range
$1.00
$1.59
52-Week Range
$0.93
$24.55
Volume
1.33 million shs
Average Volume
1.75 million shs
Market Capitalization
$92.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

Veru MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,214.1% Upside
$13.67 Price Target
Short Interest
Bearish
21.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Veru in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.32) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

762nd out of 1,009 stocks

Pharmaceutical Preparations Industry

385th out of 494 stocks


VERU stock logo

About Veru (NASDAQ:VERU) Stock

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm's breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and fin

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Stock News Headlines

How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
H.C. Wainwright Sticks to Its Buy Rating for Veru (VERU)
Veru (NASDAQ:VERU) PT Lowered to $2.00
How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
Veru: Q2 Earnings Insights
VERU Stock Earnings: Veru Misses EPS, Beats Revenue Estimates
Analyst Ratings for Veru
A Preview Of Veru's Earnings
Veru Q2 2023 Earnings Preview
Veru (VERU) Set to Announce Quarterly Earnings on Thursday
Veru (NASDAQ:VERU) Receives Buy Rating from HC Wainwright
See More Headlines
Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Company Calendar

Last Earnings
12/02/2021
Today
5/30/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
Sector
Medical
Current Symbol
NASDAQ:VERU
CUSIP
31446210
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.67
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,214.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-83,780,000.00
Net Margins
-652.36%
Pretax Margin
-652.29%

Debt

Sales & Book Value

Annual Sales
$39.35 million
Book Value
$1.01 per share

Miscellaneous

Free Float
67,909,000
Market Cap
$92.81 million
Optionable
Optionable
Beta
-0.22

Key Executives

  • Mitchell Shuster Steiner
    Chairman, President & Chief Executive Officer
  • Michele Greco
    Chief Financial & Administrative Officer
  • Robert H. Getzenberg
    Executive Vice President-Medical Affairs
  • Domingo Rodriguez
    Executive Vice President-Clinical Operations
  • K. Gary Barnette
    Chief Scientific Officer













VERU Stock - Frequently Asked Questions

Should I buy or sell Veru stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VERU shares.
View VERU analyst ratings
or view top-rated stocks.

What is Veru's stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month price objectives for Veru's shares. Their VERU share price forecasts range from $2.00 to $30.00. On average, they predict the company's share price to reach $13.67 in the next year. This suggests a possible upside of 1,214.1% from the stock's current price.
View analysts price targets for VERU
or view top-rated stocks among Wall Street analysts.

How have VERU shares performed in 2023?

Veru's stock was trading at $5.28 at the start of the year. Since then, VERU shares have decreased by 80.3% and is now trading at $1.04.
View the best growth stocks for 2023 here
.

When is Veru's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VERU earnings forecast
.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) issued its earnings results on Thursday, December, 2nd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.04. The business had revenue of $15.65 million for the quarter, compared to analysts' expectations of $18.26 million. Veru had a negative trailing twelve-month return on equity of 206.09% and a negative net margin of 652.36%. During the same quarter last year, the business earned ($0.01) earnings per share.

What ETFs hold Veru's stock?

ETFs with the largest weight of Veru (NASDAQ:VERU) stock in their portfolio include Vanguard Consumer Staples ETF (VDC), Fidelity MSCI Consumer Staples Index ETF (FSTA) and Carbon Collective Climate Solutions U.S. Equity ETF (CCSO).

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.29%), Perceptive Advisors LLC (4.82%), Geode Capital Management LLC (1.29%), Two Sigma Investments LP (0.89%), Renaissance Technologies LLC (0.62%) and Squarepoint Ops LLC (0.53%). Insiders that own company stock include Harry Fisch, K Gary Barnette, Lucy Lu, Mario Eisenberger, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends
.

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $1.04.

How much money does Veru make?

Veru (NASDAQ:VERU) has a market capitalization of $92.81 million and generates $39.35 million in revenue each year. The company earns $-83,780,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis.

How many employees does Veru have?

The company employs 252 workers across the globe.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The official website for the company is www.veruhealthcare.com. The company can be reached via phone at (305) 509-6897, via email at veruinvestor@verupharma.com, or via fax at 312-595-9122.

This page (NASDAQ:VERU) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -